Results of a Randomized, Population-Based Study of Biennial Screening Using Serum Prostate-Specific Antigen Measurement to Detect Prostate Carcinoma

Cancer

Volumn 100, Issue 7, 2004, Pages 1397-1405

  Hugosson, Jonas ^a   Aus, Gunnar ^a   Lilja, Hans ^b   Lodding, Pär ^a   Pihl, Carl Gustav ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Early detection; Epidemiology; Prostate carcinoma; Prostate specific antigen; Screening; Treatment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SWEDEN; TUMOR VOLUME;

AGED; BIOPSY, NEEDLE; HEALTH PROMOTION; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 1642390950     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20126     Document Type: Article

References (29)

1. Hugosson J, Aus G, Norlén L. Surveillance is not a viable option in treatment of localized prostate cancer. Urol Clin North Am. 1996;23:557-573.
2. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
3. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for cancer-related checkup: prostate and endometrial cancers. Cancer. 1993;43:42-46.
4. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11:167-170.
5. Mettlin C. Impact of screening on prostate cancer rates and trends. Microsc Res Tech. 2000;51:415-418.
6. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev. 2001;23:181-186.
7. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58:417-424.
8. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 1999;38:83-91.
9. Boer R, Schroeder FH. Quebec randomized controlled trial on prostate cancer screening shows no evidence of mortality reduction. Prostate. 1999;40:130-134.
10. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate cancer mortality in England and Wales and the USA. Lancet. 2000;335:1788-1789.
11. De Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomized Screening for Prostate Cancer (ERSPC) trial. Int J Cancer. 2002;98:268-273.
12. Aus G, Bergdahl S, Hugosson J, Lodding P, Pihl CG, Pileblad E. Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50-66 years. Implications for sampling order. Eur Urol. 2001;39:655-660.
13. Sobin LH, Wittekind C, editors. UICC TNM classification of malignant tumors. New York: John Wiley & Sons, 1997.
14. Gleason DF. Veterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea & Febiger, 1977:171-198.
15. Swedish National Board of Health and Welfare. Cancer incidence in Sweden [monograph online]. Available from URL: http://www.sos.se/FULLTEXT/42/2002-42-5/2002-42-5.pdf [accessed 24 February 2004].
16. Hugosson J, Aus G, Becker C, et al. Would prostate cancer detected at PSA screening develop into clinical cancer if left undiagnosed? A comparison between two population-based studies from Göteborg. BJU Int. 2000;85:1078-1084.
17. Gustafsson O, Norming U, Almgård LE, et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. J Urol. 1992;148:1827-1831.
18. Bangma CH, Kranse R, Blijenberg B, et al. The value of screening tests in the detection of prostate cancer. Part I: results of a retrospective evaluation of 1726 men. Urology. 1995;46:773-778.
19. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147:841-845.
20. Finne P, Auvinen A, Aro J, et al. Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol. 2002;41:619-627.
21. Labrie F, Candas B, Cusan L, et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology. 1996;47:212-217.
22. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996;276:1309-1315.
23. Hoedemaker RF, van der Kwast TH, Boer R, et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst. 2001;93:1153-1158.
24. Hugosson J, Lilja H, Lodding P, Pihl CG. Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers. Eur Urol. 2001;39 Suppl 4:433-434.
25. Khatami A, Damber JE, Lodding P, Pihl CG, Hugosson J. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy? A case control study. Scand J Urol Nephrol. 2003;37:213-217.
26. Duffy SW, Tabar L, Fagerberg G, et al. Breast screening, prognostic factors and survival - results from the Swedish Two-County study. Br J Cancer. 1991;64:1133-1138.
27. Tabar L, Faberberg G, Day NE, et al. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish Two-County breast cancer screening trial. Br J Cancer. 1987;55:547-551.
28. Fracheboud J, de Koning HJ, Beemsterboer PM, et al. Interval cancers in the nationwide breast cancer screening programme in the Netherlands. Br J Cancer. 1999;81:912-917.
29. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289-294.